ClinicalTrials.gg
RecruitingNCT07615010Updated Jun 26, 2026

A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure

A Phase 2 interventional study of agenT-797 and Placebo in Pneumonia, sponsored by MiNK Therapeutics. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by MiNK Therapeutics (formerly part of Agenus Inc.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 344 studies in Pneumonia with a site in United States — 41 open to participants now, 51 under way, 6 of them phase 3. Pneumonia · United States.

Planned enrollment
133rd of 263
90 · median 91
Started
2026
with 12 others
Phase 2
64 of 344
3 open now
Primary completion
2027-06
later than 26 of 48 live
Registered
340th of 344
by date

Among the 344 studies in Pneumonia with a site in United States, this one is the 133rd largest by planned enrollment of the 263 interventional ones that give a count, is one of 13 that started in 2026, is one of 64 in phase 2, reaches primary completion later than 26 of the 48 other live ones, and was the 340th registered.

Pneumonia

1,568 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

Browse Pneumonia studies →

Open to participants now

41 of the 344 studies in Pneumonia with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 159 Pneumonia studies recruiting now, 85 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 41 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 344 studies in Pneumonia with a site in United States, or all of them as a file.
02

Study summary

This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All participants will receive SOC management for severe pneumonia and acute respiratory distress syndrome (ARDS).

Read the detailed description

This trial will be conducted in 2 parts (Run-in Phase; Phase 2). The Run-in Phase is designed to characterize the baseline population of the site, where participants will receive open-label agenT-797 plus SOC. After completion of the Run-in Phase, participants will be enrolled and randomized to receive either agenT-797 plus SOC or placebo plus SOC during the double-blinded Phase 2.

03

Conditions studied

  • Pneumonia

Keywords

  • Acute Hypoxemic Respiratory Failure
  • AHRF
  • agenT-797
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Admission to an intensive care unit (ICU) with severe pneumonia of any etiology (viral, bacterial, fungal, or mixed), with and without trauma based on clinical suspicion
  • Acute hypoxemic respiratory failure (AHRF)
  • Evidence of moderate to severe acute respiratory distress syndrome (ARDS) based on Global ARDS criteria
  • Onset of severe pneumonia with AHRF ≤7 days prior to

Key Exclusion Criteria:

  • More than two vasopressors to maintain a mean arterial pressure ≥65 millimeters of mercury at the time of informed consent
  • Pregnancy or breastfeeding
  • History of cytokine release syndrome, as documented in the medical record or reported by the participant, legally authorized representative, or close relative
  • Current participation in another interventional clinical trial, or receipt of an medicinal product within 30 days prior to screening, unless reviewed and approved in writing by the medical monitor

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    agenT-797 plus SOC

    Participants will receive agenT-797 and SOC.

    Drug: agenT-797 · Drug: Standard of Care (SOC)

  • Placebo comparator
    Placebo plus SOC

    Participants will receive placebo and SOC.

    Drug: Placebo · Drug: Standard of Care (SOC)

Interventions

  • Intravenous infusion

  • DrugPlacebo

    Intravenous infusion

  • DrugStandard of Care (SOC)

    Antimicrobial therapy and corticosteroids per applicable guidelines.

06

What researchers measure

Primary outcomes

  1. Number of Deaths (All-cause Mortality)

    Time frame: Day 1 through Day 28

Secondary outcomes

  1. Number of Oxygenation Support-free Days

    Time frame: Day 1 through Day 28

  2. Time to Resolution of Hypoxemia

    Time frame: Day 1 through Day 28

  3. Number of Ventilator-free Days

    Time frame: Day 1 through Day 28

  4. Number of Intensive Care Unit-free Days

    Time frame: Day 1 through Day 28

  5. Number of Participants Experiencing New Secondary Bacterial, Antimicrobial-resistant, or Fungal Infections

    Time frame: Day 1 through Day 28

  6. Number of Antibiotic-free Days

    Time frame: Day 1 through Day 28

  7. Time to Hospital Discharge

    Time frame: Day 1 through Day 28

  8. Number of Deaths (All-cause Mortality)

    Time frame: Day 1 through Day 90

  9. Change From Baseline in Cytokine Profiles

    Cytokine profiles analyzed may include interleukin-6, tumor necrosis factor-alpha, interleukin-1-beta, interleukin-1 receptor antagonist, soluble receptor for advanced glycation end product, angiopoietin-1 and -2, and tumor necrosis factor receptor 1.

    Time frame: Baseline, Day 3, Day 7, Day 14

07

Study locations

1 of 4 sites recruiting
  • UCSF Medical Center at Parnassus Heights
    San Francisco, California 94143, United States
    Not yet recruiting
    • Michael Matthay, MD · Principal investigator
  • Children's Memorial Hermann Hospital
    Houston, Texas 77030, United States
    Not yet recruiting
    • Charles Cox, MD · Principal investigator
  • University Hospital
    San Antonio, Texas 78229, United States
    Not yet recruiting
    • Donald Jenkins, MD · Principal investigator
  • First Lviv Territorial Medical Union
    Lviv, 79059, Ukraine
    Recruiting
    • Chirstina Orlysnka, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jun 2027, 13 months after the start.

Of 64 phase 2 interventional studies under Pneumonia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 13 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
May 29, 2026
StartActual
May 26, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Aug 2027
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07615010
Lead sponsor
MiNK Therapeutics
Responsible party
Sponsor
First posted
May 29, 2026
Start date
May 26, 2026
Primary completion
Jun 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Jun 26, 2026

Study contacts

MiNK Therapeutics Clinical Trial Information
Contact
webmaster@minktherapeutics.com
1-212-994-8250

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Allogeneic Invariant Natural Killer T-cells agenT-797

Start the discussion